# iCAD vs Lunit

iCAD records 6,102 monthly visits with +6.1% month-over-month growth and Contact for Pricing pricing. Lunit records 29,181 monthly visits with -12.8% growth and Contact for Pricing pricing.

| Metric | [iCAD](https://openaitools.app/tool/icadmed-com) | [Lunit](https://openaitools.app/tool/lunit) |
| :--- | :--- | :--- |
| Website URL | https://icadmed.com | https://www.lunit.io/en |
| Categories | AI Medical Diagnosis, AI Healthcare, AI Image Recognition, AI Detector | AI Healthcare, AI Medical Diagnosis, AI Image Recognition |
| Pricing Model | Contact for Pricing | Contact for Pricing |
| Monthly Visits | 6,102 | 29,181 |
| MoM Growth Rate | +6.1% | -12.8% |
| Primary Market | United States | South Korea |
| Direct Visits | 1,806 | 8,314 |
| Review Score | 4.4 | 4.6 |
| Saved Count | 0 | 1 |
| Supported Platforms | Website | Website |

## iCAD

iCAD is a medical AI company focused on breast health. Its flagship offering, the ProFound Breast Health Suite, pairs cancer detection, density assessment and risk evaluation in one platform so radiology teams can find cancers earlier, standardise density scoring and identify high-risk women who may benefit from tailored screening schedules. The company reports two decades of experience, availability in around 50 countries and more than 40 million mammograms analysed in the last five years.

The clinical argument rests on a familiar problem: a meaningful share of breast cancers are missed in screening, especially in women with dense breast tissue, and traditional risk models are far from perfect. iCAD trains its algorithms on large, diverse mammography datasets and validates them across published clinical studies, with the goal of reducing recalls while catching more invasive disease. Media outlets and an extensive user presence sit behind implementation complexity, including integration with existing workstations and reporting systems.

Since July 2025 iCAD has been part of DeepHealth, the digital health subsidiary of RadNet, which completed its acquisition of the company. That consolidation strengthened a broader imaging AI portfolio, but the breast health products continue to be marketed and supported under the iCAD name. Procurement runs through a demo-and-quote process rather than published price lists, which is typical for clinical AI sold to hospitals and imaging centers.

**Pricing & Plans:** Contact for pricing. iCAD quotes per practice based on the modules deployed and screening volume, after a scheduled demo.

- **Cancer detection:** Highlights suspicious lesions in 2D and 3D mammograms so radiologists find more invasive and interval cancers.
- **Density assessment:** Delivers objective, consistent breast density scoring that informs personalised screening decisions.
- **Risk evaluation:** An image-based model that assesses a woman's risk of developing breast cancer before or at her next screening.
- **Clinically proven algorithms:** Four generations of algorithms trained with clinical data from 20M+ images across roughly 130 clinical sites.
- **Deployment flexibility:** Flexible on-site or cloud deployment that fits existing workstations and PACS workflows.

**Strengths:** Clinically validated across dozens of published studies and large datasets; Covers detection, density and risk in a single breast health platform; Available internationally, including FDA clearance, CE marking and Health Canada licensing; Deploys flexibly and integrates with mainstream workstations and PACS

**Limitations:** No public pricing, so budgeting requires a sales conversation; Risk module availability is limited outside the US and is investigational there; Deployment and training require buy-in from radiology IT and reading workflows

[Profile (Markdown)](https://openaitools.app/tool/icadmed-com.md)

## Lunit

Lunit is a medical AI company headquartered in Seoul, South Korea, spun out of deep-learning research and focused squarely on oncology. Rather than chasing general-purpose healthcare AI, it has built two connected product families: one that helps clinicians find cancer earlier in imaging, and one that extracts quantitative biology from tissue to guide treatment and drug development. Its technology is used across a large international footprint spanning more than 10,000 customer sites in over 70 countries, with hundreds of peer-reviewed publications and industry partnerships behind the deployments.

On the screening side, the Lunit INSIGHT family analyzes mammograms and chest radiographs. Lunit INSIGHT MMG handles 2D mammography while Lunit INSIGHT DBT covers 3D breast tomosynthesis, both designed to flag suspicious regions so radiologists can prioritize the studies that need attention most. Lunit INSIGHT CXR does the same for chest X-rays. Around these detection engines Lunit has assembled program-level tooling: density assessment, risk assessment and risk pathways, live mammography reporting, quality management, analytics, and a patient hub, so a screening service can run AI as part of its routine rather than as an isolated experiment.

On the precision oncology side, the Lunit SCOPE portfolio analyzes pathology images. Lunit SCOPE IO quantifies the tumor microenvironment and immune cell infiltration, which matters for immunotherapy strategy, while the Lunit SCOPE IHC Suite supports immunohistochemistry quantification across markers such as HER2 and PD-L1, alongside a genotype prediction tool. These products are aimed at biopharma partners, clinical trial teams, and companion diagnostic development, where reproducible quantitative readouts are the bottleneck. Because Lunit sells to hospitals, screening programs, and pharmaceutical companies, pricing is quoted directly rather than published, and regulatory status differs by market.

**Pricing & Plans:** Contact for pricing. Lunit sells enterprise software and platform licenses to hospitals, screening programs, and biopharma partners, so commercial terms and deployment costs are quoted directly through its sales team. No public price list is offered.

- **Lunit INSIGHT MMG and DBT:** Deep-learning analysis of 2D and 3D mammography that marks suspicious lesions to help radiologists detect breast cancer earlier and reduce missed findings.
- **Lunit INSIGHT CXR:** Chest X-ray analysis that highlights potential abnormalities such as nodules and other findings, supporting faster triage in high-volume radiology workflows.
- **Lunit SCOPE IO:** Tumor microenvironment analysis that quantifies tumor-infiltrating lymphocytes and immune phenotypes from pathology slides, informing immunotherapy research.
- **Lunit SCOPE IHC Suite:** AI-assisted immunohistochemistry quantification covering HER2, PD-L1, and other markers, including uIHC and a gene-expression prediction tool for standardized scoring.
- **Screening analytics and workflow tools:** Live mammography reporting, risk assessment, risk pathways, quality management, and patient-facing tools that embed AI into the wider screening program.

**Strengths:** Clinically validated radiology AI with documented regulatory clearances and published evidence; Covers two ends of the cancer pathway — screening detection and precision oncology biomarkers — in one vendor relationship; Wide real-world adoption across many countries, which means integrations and workflow lessons already exist; Strong research output and biopharma partnerships support credibility for trial and CDx work

[Profile (Markdown)](https://openaitools.app/tool/lunit.md)

## Frequently Asked Questions

### How do iCAD and Lunit compare in monthly traffic?

iCAD has 6,102 monthly visits, while Lunit has 29,181. Traffic estimates describe audience size, not product quality.

### How do their growth rates compare?

iCAD has a month-over-month growth rate of +6.1%; Lunit has -12.8%.

### How does pricing compare?

iCAD: Contact for Pricing. Contact for pricing. iCAD quotes per practice based on the modules deployed and screening volume, after a scheduled demo. Lunit: Contact for Pricing. Contact for pricing. Lunit sells enterprise software and platform licenses to hospitals, screening programs, and biopharma partners, so commercial terms and deployment costs are quoted directly through its sales team. No public price list is offered.

## Alternatives

| # | Tool Name | Monthly Visits | MoM Growth Rate | Pricing Model | Summary | Profile (Markdown) |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 1 | [Dr.Oracle](https://openaitools.app/tool/dr-oracle) | 723,847 | -1.2% | Free Trial | Guideline-directed medical answers with citations, built for clinicians | [.md](https://openaitools.app/tool/dr-oracle.md) |
| 2 | [ScanSkinAI](https://openaitools.app/tool/scanskinai) | 265,770 | -10.9% | Freemium, Paid | Free AI skin and mole scanning with optional dermatologist review | [.md](https://openaitools.app/tool/scanskinai.md) |
| 3 | [Overjet](https://openaitools.app/tool/overjet-ai) | 256,150 | +12.6% | Contact for Pricing | FDA-cleared dental AI for diagnostics, imaging, and insurance workflow | [.md](https://openaitools.app/tool/overjet-ai.md) |
| 4 | [Pearl](https://openaitools.app/tool/hellopearl-com) | 221,155 | -7.6% | Contact for Pricing | FDA-cleared dental AI for sharper diagnosis and a smoother front office | [.md](https://openaitools.app/tool/hellopearl-com.md) |
| 5 | [0xmd](https://openaitools.app/tool/0xmd-com) | 128,262 | -2.2% | Freemium | Generative AI for medical and everyday health questions | [.md](https://openaitools.app/tool/0xmd-com.md) |
| 6 | [CT Read](https://openaitools.app/tool/ct-read) | 103,157 | -5.8% | Paid | AI analysis that turns X-rays, CT scans, MRI and ultrasound into plain-language reports | [.md](https://openaitools.app/tool/ct-read.md) |
| 7 | [Empirical Health](https://openaitools.app/tool/empirical-health) | 70,517 | -28.8% | Paid | Measure, predict and prevent heart disease with data | [.md](https://openaitools.app/tool/empirical-health.md) |
| 8 | [Glass Health](https://openaitools.app/tool/glass-health) | 41,068 | -52.2% | Contact for Pricing | Frontier clinical AI grounded in leading medical evidence | [.md](https://openaitools.app/tool/glass-health.md) |
| 9 | [Oatmeal Health](https://openaitools.app/tool/oatmeal-health) | 40,264 | -44.9% | Contact for Pricing | AI lung cancer screening that finds eligible patients and scores every nodule | [.md](https://openaitools.app/tool/oatmeal-health.md) |
| 10 | [RapidAI](https://openaitools.app/tool/rapidai-com) | 20,172 | -27.9% | Contact for Pricing | Enterprise clinical AI that turns medical imaging into faster, more confident care decisions. | [.md](https://openaitools.app/tool/rapidai-com.md) |

---
Source: https://openaitools.app/compare/icadmed-com-vs-lunit

More Markdown: [Categories](https://openaitools.app/categories.md) · [Traffic rankings](https://openaitools.app/rankings.md) · [llms.txt](https://openaitools.app/llms.txt)